Oct 2012 $28 M No. 8 $10 to $50 million 9
Auspex Pharmaceuticals, Inc.: Raise no. 8, Oct 2012 × Investors in this round 9 investors had bought by the notice of Sep 6, 2013: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $28 M of $28 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andreas Sommer · Executive Officer David. A. Stamler · Executive Officer Pratik A. Shah · Executive Officer, Director David Collier · Director Rod A. Ferguson · Director Samuel Saks · Director Sep Sarshar · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Andreas Sommer, PhD, President & CEO. Source: SEC Form D and 1 amendment, newest notice filed Sep 6, 2013. Read the notice at the SEC .
equity SEC Jul 2012 $2 M No. 7 Under $2 million 5
Auspex Pharmaceuticals, Inc.: Raise no. 7, Jul 2012 × Investors in this round 5 investors had bought by the notice of Jul 31, 2012: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $3 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, other: Promissory Notes convertible into Preferred Stock and Warrants to purchase shares of Preferred Stock were issued in connection with the Offering
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andreas C. Sommer · Executive Officer David C. Stamler · Executive Officer Lawrence C. Fritz · Executive Officer, Director David C. Collier · Director Pratik C. Shah · Director Samuel C. Saks · Director Sep C. Sharshar · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Warrants for the purchase of Preferred Stock were issued in connection with the Offering for no additional consideration. The aggregate number of warrant shares is contingent on a formula set forth in each of the warrants.”Signed by Lawrence C. Fritz, President & CEO. Source: SEC Form D, newest notice filed Jul 31, 2012. Read the notice at the SEC .
debt, options SEC Dec 2011 $3 M No. 6 $2 to $10 million 7
Auspex Pharmaceuticals, Inc.: Raise no. 6, Dec 2011 × Investors in this round 7 investors had bought by the notice of Jan 11, 2012: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $6 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, other: Promissory Notes convertible into Preferred Stock and Warrants to purchase shares of Preferred Stock were issued in connection with the Offering.
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andreas A. Sommer · Executive Officer David A. Stamler · Executive Officer Lawrence C. Fritz · Executive Officer, Director David Collier · Director Pratik Shah · Director Samuel Saks · Director Sepehr Sarshar · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Warrants for the purchase of Pref Stock were issued at the Offering. No additional consideration was received for the Warrants. The # of warrant shares issuable upon exercise of the Warrants is contingent upon a formula set forth in each of the Warrants.”Signed by Lawrence C. Frtiz, President and CEO. Source: SEC Form D, newest notice filed Jan 11, 2012. Read the notice at the SEC .
debt, options SEC Jul 2010 $12 M No. 5 $10 to $50 million 8
Auspex Pharmaceuticals, Inc.: Raise no. 5, Jul 2010 × Investors in this round 8 investors had bought by the notice of Jul 16, 2010: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $12 M of $12 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andreas Gary Sommer · Executive Officer Pratik Shah · Executive Officer, Director R. Gary Gilmore · Executive Officer Samuel Saks · Executive Officer, Director David Collier · Director Sepehr Sarshar · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by R. Gary Gilmore, CFO and Secretary. Source: SEC Form D, newest notice filed Jul 16, 2010. Read the notice at the SEC .
equity SEC Jan 2010 $2 M No. 4 $2 to $10 million 6
Auspex Pharmaceuticals, Inc.: Raise no. 4, Jan 2010 × Investors in this round 6 investors had bought by the notice of Feb 26, 2010: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, other: Promissory Notes convertible into Preferred Stock and Warrants to purchase shares of Preferred Stock were issued in connection with the Offering.
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andreas Gary Sommer · Executive Officer Pratik Shah · Executive Officer, Director R. Gary Gilmore · Executive Officer Ron Gary Newbold · Executive Officer David Collier · Director Samuel Saks · Director Sep Sarshar · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “No additional consideration was received for the issuance of the warrants. The aggregate number of warrant shares issuable upon exercise of the warrants is contingent upon a formula set forth in each of the warrants.”Signed by R. Gary Gilmore, CFO and Secretary. Source: SEC Form D, newest notice filed Feb 26, 2010. Read the notice at the SEC .
debt, options SEC Oct 2009 $2 M No. 3 $2 to $10 million 5
Auspex Pharmaceuticals, Inc.: Raise no. 3, Oct 2009 × Investors in this round 5 investors had bought by the notice of Oct 22, 2009: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, other: Promissory Notes convertible into Preferred Stock and Warrants to purchase shares of Preferred Stock were issued in connection with the Offering.
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andreas Gary Sommers · Executive Officer Pratik Shah · Executive Officer, Director R. Gary Gilmore · Executive Officer Ron Gary Newbold · Executive Officer David Collier · Director Sam Sachs · Director Sep Sarshar · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “No additional consideration was received for the issuance of the warrants. The aggregate number of warrant shares issuable upon exercise of the warrants is contingent upon a formula set forth in each of the warrants.”Signed by R. Gary Gilmore, CFO and Secretary. Source: SEC Form D, newest notice filed Oct 22, 2009. Read the notice at the SEC .
debt, options SEC May 2009 $3 M No. 2 $2 to $10 million 7
Auspex Pharmaceuticals, Inc.: Raise no. 2, May 2009 × Investors in this round 7 investors had bought by the notice of Aug 3, 2009: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, other: Promissory Notes convertible into Preferred Stock and Warrants to purchase shares of Preferred Stock were issued in connection with the Offering.
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Michael Grey · Executive Officer, Director R. Gary Gilmore · Executive Officer Sep Sarshar · Executive Officer, Director Thomas Gant · Executive Officer, Director David Collier · Director Pratik Shah · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by R. Gary Gilmore, CFO and Secretary. Source: SEC Form D, newest notice filed Aug 3, 2009. Read the notice at the SEC .
debt, options SEC Jun 2007 $14 M No. 1 $10 to $50 million 5
Auspex Pharmaceuticals, Inc.: Raise no. 1, Jun 2007 × Investors in this round 5 investors had bought by the notice of Jul 30, 2010: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $14 M of $14 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andreas Gary Sommer · Executive Officer Pratik Shah · Executive Officer, Director R. Gary Gilmore · Executive Officer Samuel Saks · Executive Officer, Director David Collier · Director Sepehr Sarshar · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by R. Gary Gilmore, CFO and Secretary. Source: SEC Form D, newest notice filed Jul 30, 2010. Read the notice at the SEC .
equity SEC